-
1
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
-
(2005)
Ca-A Cancer Journal for Clinicians
, vol.55
, Issue.2
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
2
-
-
0034856294
-
Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference
-
DOI 10.1016/S0168-8278(01)00130-1, PII S0168827801001301
-
Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430 (Pubitemid 32844200)
-
(2001)
Journal of Hepatology
, vol.35
, Issue.3
, pp. 421-430
-
-
Bruix, J.1
Sherman, M.2
Llovet, J.M.3
Beaugrand, M.4
Lencioni, R.5
Burroughs, A.K.6
Christensen, E.7
Pagliaro, L.8
Colombo, M.9
Rodes, J.10
-
3
-
-
28844480321
-
Management of hepatocellular carcinoma
-
DOI 10.1002/hep.20933
-
Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236 (Pubitemid 43112690)
-
(2005)
Hepatology
, vol.42
, Issue.5
, pp. 1208-1236
-
-
Bruix, J.1
Sherman, M.2
-
4
-
-
0141491273
-
Hepatocellular carcinoma
-
DOI 10.1016/S0140-6736(03)14964-1
-
Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917 (Pubitemid 37518510)
-
(2003)
Lancet
, vol.362
, Issue.9399
, pp. 1907-1917
-
-
Llovet, J.M.1
Burroughs, A.2
Bruix, J.3
-
5
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
6
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
-
7
-
-
77649228957
-
Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: A phase I/II study
-
Zhao JD, Liu J, Ren ZG et al (2010) Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity- modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol 5:12-18
-
(2010)
Radiat Oncol
, vol.5
, pp. 12-18
-
-
Zhao, J.D.1
Liu, J.2
Ren, Z.G.3
-
8
-
-
0014187807
-
Growth inhibitory effect of cardiac glycosides and aglycones on neoplastic cells: In vitro and in vivo studies
-
Shiratori O (1967) Growth inhibitory effect of cardiac glycosides and aglycones on neoplastic cells: in vitro and in vivo studies. Gann 58:521-528
-
(1967)
Gann
, vol.58
, pp. 521-528
-
-
Shiratori, O.1
-
9
-
-
46449105600
-
Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells
-
Takai N, Ueda T, Nishida M et al (2008) Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med 21:637-643
-
(2008)
Int J Mol Med
, vol.21
, pp. 637-643
-
-
Takai, N.1
Ueda, T.2
Nishida, M.3
-
10
-
-
34249825771
-
The α1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers
-
DOI 10.1002/path.2172
-
Mijatovic T, Roland I, Van Quaquebeke E et al (2007) The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 212:170-179 (Pubitemid 46852095)
-
(2007)
Journal of Pathology
, vol.212
, Issue.2
, pp. 170-179
-
-
Mijatovic, T.1
Roland, I.2
Van Quaquebeke, E.3
Nilsson, B.4
Mathieu, A.5
Van Vynckt, F.6
Darro, F.7
Blanco, G.8
Facchini, V.9
Kiss, R.10
-
11
-
-
0037304261
-
Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells
-
DOI 10.1002/pros.10172
-
Yeh JY, Huang WJ, Kan SF et al (2003) Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54:112-124 (Pubitemid 36120327)
-
(2003)
Prostate
, vol.54
, Issue.2
, pp. 112-124
-
-
Yeh, J.-Y.1
Huang, W.J.2
Kan, S.-F.3
Wang, P.S.4
-
12
-
-
36249023658
-
Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside
-
DOI 10.1177/1534735407309623
-
Newman RA, Kondo Y, Yokoyama T et al (2007) Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther 6:354-364 (Pubitemid 350136018)
-
(2007)
Integrative Cancer Therapies
, vol.6
, Issue.4
, pp. 354-364
-
-
Newman, R.A.1
Kondo, Y.2
Yokoyama, T.3
Dixon, S.4
Cartwright, C.5
Chan, D.6
Johansen, M.7
Peiying Yang8
-
13
-
-
38149063511
-
Preparative isolation of bufalin and cinobufagin from Chinese traditional medicine ChanSu
-
Yang Z, Luo H, Wang H et al (2008) Preparative isolation of bufalin and cinobufagin from Chinese traditional medicine ChanSu. J Chromatogr Sci 46:81-85
-
(2008)
J Chromatogr Sci
, vol.46
, pp. 81-85
-
-
Yang, Z.1
Luo, H.2
Wang, H.3
-
14
-
-
76549129820
-
Drug combination studies and their synergy quantification using the Chou-Talalay method
-
Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440-446
-
(2010)
Cancer Res
, vol.70
, pp. 440-446
-
-
Chou, T.C.1
-
15
-
-
79951578559
-
Calreticulin expression levels and endoplasmic reticulum during late oogen-esis and early embryogenesis of Rhodnius prolixus Stahl
-
doi:10.1007/s11033-010-0290-0
-
Ramos IB, Campos CB, Sorgine MH et al (2011) Calreticulin expression levels and endoplasmic reticulum during late oogen-esis and early embryogenesis of Rhodnius prolixus Stahl. Mol Biol Rep 38(3):1757-1767. doi:10.1007/s11033- 010-0290-0
-
(2011)
Mol Biol Rep
, vol.38
, Issue.3
, pp. 1757-1767
-
-
Ramos, I.B.1
Campos, C.B.2
Sorgine, M.H.3
-
16
-
-
58149376548
-
Molecular mechanisms of hepatocellular carcinoma
-
Aravalli RN, Steer CJ, Cressman EN (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48:2047-2063
-
(2008)
Hepatology
, vol.48
, pp. 2047-2063
-
-
Aravalli, R.N.1
Steer, C.J.2
Cressman, E.N.3
-
17
-
-
33748063941
-
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
-
DOI 10.1016/j.advenzreg.2006.01.004, PII S0065257106000033, Proceedings of teh 46th International Sumposium on Regulation of the Enzym Activity ans Synthesis in Normal and Neoplastic Tissues
-
McCubrey JA, Steelman LS, Abrams SL et al (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249-279 (Pubitemid 44301348)
-
(2006)
Advances in Enzyme Regulation
, vol.46
, Issue.1
, pp. 249-279
-
-
McCubrey, J.A.1
Steelman, L.S.2
Abrams, S.L.3
Lee, J.T.4
Chang, F.5
Bertrand, F.E.6
Navolanic, P.M.7
Terrian, D.M.8
Franklin, R.A.9
D'Assoro, A.B.10
Salisbury, J.L.11
Mazzarino, M.C.12
Stivala, F.13
Libra, M.14
-
18
-
-
55749088393
-
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
-
Wilhelm SM, Adnane L, Newell P et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 3129-3140
-
-
Wilhelm, S.M.1
Adnane, L.2
Newell, P.3
-
19
-
-
70049099306
-
Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study
-
Zhang Z, Zhou X, Shen H et al (2009) Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 7:41
-
(2009)
BMC Med
, vol.7
, pp. 41
-
-
Zhang, Z.1
Zhou, X.2
Shen, H.3
-
20
-
-
67649438633
-
Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepato-cellular carcinoma cells
-
Dai R, Chen R, Li H (2009) Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepato-cellular carcinoma cells. Int J Oncol 34:1749-1757
-
(2009)
Int J Oncol
, vol.34
, pp. 1749-1757
-
-
Dai, R.1
Chen, R.2
Li, H.3
-
21
-
-
0033607784
-
Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt
-
Rommel C, Clarke BA, Zimmermann S et al (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286:1738-1741 (Pubitemid 129515881)
-
(1999)
Science
, vol.286
, Issue.5445
, pp. 1738-1741
-
-
Rommel, C.1
Clarke, B.A.2
Zimmermann, S.3
Nunez, L.4
Rossman, R.5
Reid, K.6
Moelling, K.7
Yancopoulos, G.D.8
Glass, D.J.9
-
22
-
-
80052746970
-
Bufalin induces reactive oxygen species dependent bax translocation and apoptosis in ASTC-a-1 cells
-
doi: 10.1093/ecam/nep082 (in press)
-
Sun L, Chen T, Wang X et al (2009) Bufalin induces reactive oxygen species dependent bax translocation and apoptosis in ASTC-a-1 cells. Evid Based Complement Alternat Med doi: 10.1093/ecam/nep082 (in press)
-
(2009)
Evid Based Complement Alternat Med
-
-
Sun, L.1
Chen, T.2
Wang, X.3
-
23
-
-
57349119864
-
PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells
-
Li D, Qu X, Hou K et al (2009) PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs 20:59-64
-
(2009)
Anticancer Drugs
, vol.20
, pp. 59-64
-
-
Li, D.1
Qu, X.2
Hou, K.3
-
24
-
-
56849086301
-
AKT and oxidative stress team up to kill cancer cells
-
Dolado I, Nebreda AR (2008) AKT and oxidative stress team up to kill cancer cells. Cancer Cell 14:427-429
-
(2008)
Cancer Cell
, vol.14
, pp. 427-429
-
-
Dolado, I.1
Nebreda, A.R.2
-
25
-
-
56849118516
-
Akt determines rep-licative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis
-
Nogueira V, Park Y, Chen CC et al (2008) Akt determines rep-licative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14:458-470
-
(2008)
Cancer Cell
, vol.14
, pp. 458-470
-
-
Nogueira, V.1
Park, Y.2
Chen, C.C.3
-
26
-
-
63649129676
-
Coadministration of so-rafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro
-
Chen FS, Cui YZ, Luo RC et al (2008) Coadministration of so-rafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 28:1684-1687
-
(2008)
Nan Fang Yi Ke da Xue Xue Bao
, vol.28
, pp. 1684-1687
-
-
Chen, F.S.1
Cui, Y.Z.2
Luo, R.C.3
-
27
-
-
63149135554
-
Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells
-
Wu J, Luo RC, Zhang H et al (2008) Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao 28:639-641
-
(2008)
Nan Fang Yi Ke da Xue Xue Bao
, vol.28
, pp. 639-641
-
-
Wu, J.1
Luo, R.C.2
Zhang, H.3
-
28
-
-
79955755223
-
Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402
-
Li N, Zhang Y, Wu T et al (2009) Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402. Ai Zheng 28:838-843
-
(2009)
Ai Zheng
, vol.28
, pp. 838-843
-
-
Li, N.1
Zhang, Y.2
Wu, T.3
-
29
-
-
52649085241
-
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
-
Wang Z, Zhou J, Fan J et al (2008) Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 14:5124-5130
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5124-5130
-
-
Wang, Z.1
Zhou, J.2
Fan, J.3
|